In the article entitled “Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan” [Liver Cancer. 2024; DOI: 10.1159/000537686] by Teng et al., the authors noted that the cited reference numbers in Table 3 were wrong. The correct Table 3 is shown here.
Table 3.
Overview of phase-3 first-line clinical trials for systemic therapies in advanced-stage HCC
| Trial name (year) | Arms | OS, median (95% CI), months | HR of OS (95% CI) | PFS, median (95% CI), months | HR of PFS (95% CI) | ORR by RECIST 1.1, % |
|---|---|---|---|---|---|---|
| SHARP [102] (2008) |
Sorafenib Placebo |
10.7 (9.4-13.3) 7.9 (6.8-9.1) |
0.69 (0.55-0.87) | 5.5 (4.1-6.9) 2.8 (2.7-3.9) |
0.58 (0.45-0.74) | 2.0 1.0 |
|
| ||||||
| REFLECT [103] (2018) |
Lenvatinib Placebo |
13.6 (12.1-14.9) 12.3 (10.4-13.9) |
0.92 (0.79-1.06) | 7.4 (6.9-8.8) 3.7 (3.6-4.6) |
0.66 (0.57-0.77) | 18.8 6.5 |
|
| ||||||
| IMbrave150 [99] (2020) |
Atezolizumab plus Bevacizumab Sorafenib |
19.2 (17.0-23.7) 13.4 (11.4-16.9) |
0.66 (0.52-0.85) | 6.9 (5.7-8.6) 4.3 (4.0-5.6) |
0.65 (0.53-0.81) | 27.3 |
|
| ||||||
| ORIENT-32 [105] (2021) |
Sintilimab plus Bevacizumab biosimilar Sorafenib |
Not reached 10.4 (8.5-not reached) |
0.57 (0.43-0.75) | 4.6 (4.1-5.7) 2.8 (2.7-3.2) |
0.56 (0.46-0.70) | 21.0 7.0 |
|
| ||||||
| HIMALAYA [101] (2022) |
A: Tremelimumab plus Durvalumab B: Durvalumab C: Sorafenib |
16.4 (14.2-19.6) 16.6 (14.1-19.1) 13.8 (12.3-16.1) |
A vs. C: 0.78 (0.65-0.92) B vs. C: 0.86 (0.73-1.03) |
3.8 (3.7-5.3) 3.7 (3.2-3.8) 4.1 (3.8-5.5) |
A vs. C: 0.90 (0.77-1.05) B vs. C: 1.02 (0.88-1.19) |
20.1 17.0 5.1 |
|
| ||||||
| RATIONALE-301 [104] (2022) |
Tislelizumab Sorafenib |
15.9 14.1 |
0.85 (0.71-1.02) | 2.2 3.6 |
1.1 (0.92-1.33) | 14.3 5.4 |
|
| ||||||
| COSMIC-312 [106] (2022) |
Cabozantinib plus Atezolizumab Sorafenib |
15.4 (96%CI 13.7-17.7) 15.5 (96%CI 12.1-not reached) |
0.90 (0.69-1.18) | 6.8 (99%CI 5.6-8.3) 4.2 (99%CI 2.8-7.0) |
0.63 (0.44-0.91) | 11 4 |
|
| ||||||
| LEAP-002 [107] (2022) |
Lenvatinib plus Pem-brolizumab Lenvatinib plus placebo |
21.2 (19.0-23.6) 19.0 (17.2-21.7) |
0.84 (0.71-0.99) | 8.2 (6.4-8.4) 8.0 (6.3-8.2) |
0.87 (0.73-1.02) | 26.1 17.5 |
|
| ||||||
| CARES-310 [108] (2023) |
Camrelizumab plus Rivoceranib Sorafenib |
22.1 (19.1-27.2) 15.2 (13.0-18.5) |
0.62 (0.49-0.80) | 5.6 (5.5-6.3) 3.7 (2.8-3.7) |
0.52 (0.41-0.65) | 25 6 |
CI, confidence interval; HR, hazard ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.